Scientific Reports (Apr 2024)

Loss of Y in regulatory T lymphocytes in the tumor micro-environment of primary colorectal cancers and liver metastases

  • Magdalena Wójcik,
  • Ulana Juhas,
  • Elyas Mohammadi,
  • Jonas Mattisson,
  • Kinga Drężek-Chyła,
  • Edyta Rychlicka-Buniowska,
  • Bożena Bruhn-Olszewska,
  • Hanna Davies,
  • Katarzyna Chojnowska,
  • Paweł Olszewski,
  • Michał Bieńkowski,
  • Michał Jankowski,
  • Olga Rostkowska,
  • Andrzej Hellmann,
  • Rafał Pęksa,
  • Jacek Kowalski,
  • Marek Zdrenka,
  • Jarek Kobiela,
  • Wojciech Zegarski,
  • Wojciech Biernat,
  • Łukasz Szylberg,
  • Piotr Remiszewski,
  • Jakub Mieczkowski,
  • Natalia Filipowicz,
  • Jan P. Dumanski

DOI
https://doi.org/10.1038/s41598-024-60049-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Male sex is a risk factor for colorectal cancer (CRC) with higher illness burden and earlier onset. Thus, we hypothesized that loss of chromosome Y (LOY) in the tumor micro-environment (TME) might be involved in oncogenesis. Previous studies show that LOY in circulating leukocytes of aging men was associated with shorter survival and non-hematological cancer, as well as higher LOY in CD4 + T-lymphocytes in men with prostate cancer vs. controls. However, nothing is known about LOY in leukocytes infiltrating TME and we address this aspect here. We studied frequency and functional effects of LOY in blood, TME and non-tumorous tissue. Regulatory T-lymphocytes (Tregs) in TME had the highest frequency of LOY (22%) in comparison to CD4 + T-lymphocytes and cytotoxic CD8 + T-lymphocytes. LOY score using scRNA-seq was also linked to higher expression of PDCD1, TIGIT and IKZF2 in Tregs. PDCD1 and TIGIT encode immune checkpoint receptors involved in the regulation of Tregs function. Our study sets the direction for further functional research regarding a probable role of LOY in intensifying features related to the suppressive phenotype of Tregs in TME and consequently a possible influence on immunotherapy response in CRC patients.